Market revenue in 2023 | USD 4,259.5 million |
Market revenue in 2030 | USD 5,363.6 million |
Growth rate | 3.3% (CAGR from 2023 to 2030) |
Largest segment | Subunit vaccines |
Fastest growing segment | Subunit Vaccines |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Subunit Vaccines, Inactivated, Live Attenuated, MRNA vaccines, Viral vector vaccines |
Key market players worldwide | Serum Institute of India Pvt. Ltd., CSL Ltd, Sanofi SA, GSK PLC, Merck & Co Inc, Pfizer Inc, Sinovac Biotech Ltd, BioNTech SE ADR, AstraZeneca PLC, Moderna Inc |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to vaccine market will help companies and investors design strategic landscapes.
Subunit vaccines was the largest segment with a revenue share of 34.12% in 2023. Horizon Databook has segmented the India vaccine market based on subunit vaccines, inactivated, live attenuated, mrna vaccines, viral vector vaccines covering the revenue growth of each sub-segment from 2018 to 2030.
India has a flourishing pharmaceutical sector owing to the emergence of generic manufacturers and the presence of leading pharmaceutical players. The growth of India influenza vaccines market is driven by increasing prevalence of influenza in the country, coupled with several awareness campaigns arranged by local governments.
In addition, rising government efforts to bring next-generation influenza vaccines into the country is another factor propelling the country’s market. For instance, in August 2018, India and the EU announced a collaboration to develop a next-generation flu vaccine for people in India.
Furthermore, in August 2022, Novavax announced a collaboration with the SII to investigate and develop vaccines against malaria, flu, and RSV in babies. Moreover, Cervavac, India's inaugural indigenous vaccine against cervical cancer, created and produced by the SII in Pune, is now accessible in the private market.
Horizon Databook provides a detailed overview of country-level data and insights on the India vaccine market , including forecasts for subscribers. This country databook contains high-level insights into India vaccine market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
No related regions found.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account